SeQuent Scientific Ltd
NSE:SEQUENT
SeQuent Scientific Ltd
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
First Merged Results: Q3 FY '26 marks the first quarterly results of the merged Sequent and Viyash entity, highlighting integration progress and combined scale.
Strong Revenue Growth: Revenue for Q3 FY '26 rose 10.9% year-on-year to INR 8.5 billion, with 9-month revenue up 11.9% to INR 25 billion.
Profitability Surge: Adjusted EBITDA jumped 64.4% year-on-year in Q3 to INR 1.8 billion, with margins expanding to 21.6%.
Margin Expansion: Gross margins improved to 54.5% in Q3 and 54% for the 9-month period, with EBITDA margins surpassing 20%.
Low Debt & Strong Balance Sheet: Net debt to EBITDA reduced to less than 0.4x, providing headroom for both organic investments and selective M&A.
Merger Synergies Ahead: Most merger synergies are not yet realized; management expects significant benefits to flow in FY '27.
One-Time Expenses: Q3 included INR 413 million of merger-related costs and a tax charge of INR 77 million, both identified as one-time items.
Guidance Reaffirmed: Management is confident of sustaining 20% EBITDA margins and achieving INR 4,000 crore revenue and 20% EBITDA by FY '27, a year ahead of previous targets.
